A Gene Delivery Study to Evaluate the Safety and Expression of Delandistrogene Moxeparvovec in Participants Under the Age of Four With Duchenne Muscular Dystrophy (DMD)
Phase 2
Recruiting
- Conditions
- Duchenne Muscular Dystrophy
- Interventions
- Genetic: delandistrogene moxeparvovec
- Registration Number
- NCT06128564
- Lead Sponsor
- Hoffmann-La Roche
- Brief Summary
This open-label, single-arm study will evaluate the safety and expression of delandistrogene moxeparvovec in participants with DMD. Participants will be in the study for approximately 264 weeks.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Male
- Target Recruitment
- 21
Inclusion Criteria
- Cohort A: >=3 years of age to <4 years of age
- Cohort B: >=2 years of age to <3 years of age
- Cohort C: >6 months to <2 years of age
- Cohort D: <=6 months of age
- Has a definitive diagnosis of DMD prior to screening based on documentation of clinical findings and prior confirmatory genetic testing using a clinical diagnostic genetic test
- Able to cooperate with age-appropriate motor assessment testing
- A pathogenic frameshift mutation or premature stop codon contained between exons 18 and 79 (inclusive)
Exclusion Criteria
- Exposure to gene therapy, investigational medication, or any treatment designed to increase dystrophin expression, within protocol-specified time limits
- Recombinant Adeno-Associated Virus Serotype rh74 (rAArh74) antibody titers are elevated, as per protocol-specified criteria
- Receiving regular oral corticosteroids as a treatment for DMD or planning to receive oral corticosteroids as a treatment for DMD within 1 year of baseline
- Presence of any other clinically significant illness, medical condition, or requirement for chronic drug treatment that in the opinion of the Investigator creates unnecessary risk for gene transfer
- Medical condition or extenuating circumstance that, in the opinion of the investigator, might compromise the participant's ability to comply with the protocol required testing or procedures, or compromise the participant's well-being or safety, or clinical interpretability
Other inclusion or exclusion criteria could apply
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description Delandistrogene Moxeparvovec delandistrogene moxeparvovec Participants will receive a single intravenous (IV) infusion of delandistrogene moxeparvovec on Day 1.
- Primary Outcome Measures
Name Time Method Percentage of Participants with a Treatment-emergent Adverse Event (TEAE), Serious Adverse Event (SAE), and Adverse Event of Special Interest (AESI) Baseline up to Week 260
- Secondary Outcome Measures
Name Time Method Change in Quantity of Delandistrogene Moxeparvovec Dystrophin as Measured by Western Blot Baseline, Week 12
Trial Locations
- Locations (7)
Chr de La Citadelle
🇧🇪Liege, Belgium
Hôpital Necker-Enfants Malades
🇫🇷Paris, France
Universitätsklinikum Essen
🇩🇪Essen, Germany
PU A. Gemelli, Università Cattolica del Sacro Cuore
🇮🇹Roma, Lazio, Italy
Hospital Sant Joan De Deu
🇪🇸Esplugues De Llobregas, Barcelona, Spain
Great Ormond Street Hospital for Children
🇬🇧London, United Kingdom
John Radcliffe Hospital
🇬🇧Oxford, United Kingdom